Physician profile
Wei Lee Wan
NPI 1558414193
$6,356.67
in general payments reported to CMS, 2019-2025
18 companies · $927 in 2025
The $927 reported for 2025 was more than what 75% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,501 · 2020: $116 · 2021: $356 · 2022: $507 · 2023: $1,112 · 2024: $838 · 2025: $927.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,877.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,876.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $2,469.81 | 2019-2025 | Tecnis Iol, Veritas Vision System, Tecnis Iol |
| Glaukos Corporation | $951.52 | 2020-2025 | Idosetr, Istent Trabecular Micro-Bypass System Model Is3, Idose |
| Abbvie INC. | $596.03 | 2022-2024 | Xen Glaucoma Treatment System, Durysta |
| Alcon Vision LLC | $578.91 | 2019-2025 | Hydrus Microstent, Rocklatan, Clareon Panoptix Pro |
| Ivantis, INC | $294.09 | 2019 | |
| Ocular Therapeutix, INC. | $264.98 | 2021-2025 | Dextenza |
| Bausch & Lomb Americas INC. | $244.72 | 2022-2025 | Envista Mx60 Iol, Envista Aspire Iol, Vyzulta |
| Allergan, INC. | $174.63 | 2019-2022 | |
| Aerie Pharmaceuticals, INC. | $124.75 | 2019 | |
| Amgen INC. | $116.33 | 2024 | Tepezza |
| Ani Pharmaceuticals, INC. | $116.33 | 2025 | Purified Cortrophin Gel |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $115.93 | 2019 | |
| Astellas Pharma US INC | $110.08 | 2023 | Izervay |
| Sun Pharmaceutical Industries INC. | $65.81 | 2021-2023 | Cequa |
| Eyepoint US, INC. | $65.73 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $24.32 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $21.91 | 2025 | Xdemvy |
| Rxsight INC | $20.79 | 2023 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge, Rxsight Injector Handpiece |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wei Wan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.